Company intelligence / Profile preview

Hummingbird Systems

Ownership: Private
Development stage: Other

Overview

Hummingbird Bioscience is a clinical-stage biotech developing precision biotherapeutics using its RAD platform. Its lead programs are monoclonal antibodies targeting novel epitopes on HER3 and VISTA, both in Phase I trials. The company has also outlicensed an ADC program expected to enter the clinic in 2025. Early results highlight strong biological rationale and potential for deep/durable responses; full clinical data not yet public.

Therapeutic areas: ImmunologyOncology
Modalities: Monoclonal antibodyAntibody-drug conjugateBiologic
Industry: Biotech

Partnerships

Synaffix B.V.A*STAR SingaporeMIT academic collaborationsImmunome Inc.

Beyond the preview

Go deeper on Hummingbird Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hummingbird Systems.

Explore the full profile